Compare SPCB & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | FLNA |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.2M | 61.8M |
| IPO Year | 2004 | 2000 |
| Metric | SPCB | FLNA |
|---|---|---|
| Price | $9.32 | $0.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.00 | $6.50 |
| AVG Volume (30 Days) | 49.2K | ★ 702.8K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,119,000.00 |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $12.31 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $0.64 |
| 52 Week High | $12.87 | $2.03 |
| Indicator | SPCB | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 34.93 |
| Support Level | $8.75 | N/A |
| Resistance Level | $9.58 | $1.05 |
| Average True Range (ATR) | 0.45 | 0.04 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 75.13 | 3.74 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.